The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. With ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...

Your first self-injection should be performed at your dermatologist’s office so they can show you the right way to give yourself injections under the skin. After this training, and with your ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...

The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients ...

Findings at week 12 showed a significantly greater proportion of patients treated with the SC induction regimen achieved clinical remission compared with those who received placebo. The Food and Drug ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has approved guselkumab, an interleukin-23 ...

Tremfya (guselkumab) has potential interactions with certain other medications, such as abatacept (Orencia) and paroxetine (Brisdelle, Paxil). Using Tremfya may affect how your body responds to ...

Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...